The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for to support natural history studies for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed […]
FDA announces 2022 grant funding opportunity for rare disease research
The Food and Drug Administration
Orphan Products Natural History Grants: New Funding Opportunity
FDA
Orphan Products Natural History Grants: New Funding Opportunity
FDA’s Office of Orphan Product Development (OOPD) has opened grant opportunity to support efficient and innovative natural history studies that advance medical product development in rare diseases with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to […]
FDA Upcoming Grant Funding Opportunity for Rare Disease Research
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2021 – FY 2022 to support innovative and efficient clinical trials for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the […]
FDA Upcoming Grant Funding Opportunity for Rare Disease Research
The Food and Drug Administration
New grant funding opportunity: FDA OOPD Orphan Products Grants Program
June 23rd 2020 The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2021 – FY 2022 to support innovative and efficient clinical trials for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will […]
New grant funding opportunity: FDA OOPD Orphan Products Grants Program
June 23rd 2020 The Food and Drug Administration
NINDS creates the Ultra-Rare Gene-based Therapy (URGenT) Network
The National Institute of Neurological Disorders and Stroke (NINDS) recently created the Ultra-Rare Gene-Based Therapy (URGenT) Network. The URGenT Network supports the development of state-of-the-art gene-based therapies for ultra-rare neurological diseases, which affect as few or fewer than one in fifty thousand people. It supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) […]
New Rare Care Centre will coordinate rare disease care at Perth Children’s Hospital, Western Australia
On February 25th, IRDiRC member Western Australian Department of Health announced the launch of a new Rare Care Centre in Perth, Western Australia, which will provide a holistic model of care for children with rare and undiagnosed diseases. Based at Perth Children’s Hospital (PCH), the Centre has secured funding from leading Australian philanthropists and foundation, with a total commitment of […]